The Role of miRNA in Group 3 Pulmonary Hypertension (NCT06714136) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
The Role of miRNA in Group 3 Pulmonary Hypertension
Italy27 participantsStarted 2022-10-10
Plain-language summary
This study recognizes the substantial value of lung tissue obtained from explanted lungs for fundamental research purposes.By analyzing pulmonary tissue affected by pulmonary hypertension, it is possible to discover shared pathogenetic mechanisms between these two groups and to gain a deeper understanding of the mechanisms underlying pulmonary hypertension.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
* Patients who underwent lung transplantation at the AOU IRCCS Policlinico Sant'Orsola in Bologna and the IRCCS Fondazione Policlinico San Matteo in Pavia (satellite center) from January 1, 2010, to December 31, 2021.
* Diagnosis of idiopathic pulmonary arterial hypertension, idiopathic pulmonary fibrosis, or chronic obstructive pulmonary disease.
* Patients who underwent at least one pre-transplant right heart catheterization in clinically stable conditions, with findings of mPAP ≥ 25 mmHg, PVR \> 3 WU, and PCP \< 15 mmHg.
* Suitability of lung explant tissue available in the archives of the participating pathology departments: presence of at least 3 pulmonary arterioles in each specimen.
* Acquisition of informed consent. Exclusion criteria
* Unsuitability of lung tissue for molecular biology investigations (due to preservation issues or deterioration of the necessary arteriolar structures).
* Patients with active neoplastic diseases.
What they're measuring
1
miRNAs espression
Timeframe: 18 months
Trial details
NCT IDNCT06714136
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna